Study of octaplex dosing accuracy: An in vitro analysis

Thrombosis and Haemostasis

Volumn 107, Issue 2, 2012, Pages 248-252

  Patriquin, Christopher J ^a   Chin Yee, Ian H ^a   Kovacs, Michael J ^a   Lazo Langner, Alejandro ^a   Keeney, Michael ^b   Hsia, Cyrus C ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Factor concentrates; Thrombosis; Vitamin K dependent factors

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT THROMBOPLASTIN; WARFARIN;

ADULT; ARTICLE; BLOOD CLOTTING TEST; BODY SURFACE; CLINICAL ARTICLE; DOSE CALCULATION; DRUG DOSE INCREASE; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PARTIAL THROMBOPLASTIN TIME; PLASMA VOLUME; PRIORITY JOURNAL; PROTHROMBIN TIME; SINGLE DRUG DOSE;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BODY WEIGHT; DRUG DOSAGE CALCULATIONS; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; WARFARIN;

EID: 84856674647     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-09-0610     Document Type: Article

References (23)

1. Vigue B. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care 2009; 13: 209.
2. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004; 24: 1311-1316.
3. Dentali F, Crowther MA. Management of excessive anticoagulant effect due to vitamin K antagonists. Hematology Am Soc Hematol Educ Program 2008; 266-270.
4. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000; 160: 967-973.
5. Hylek EM, Chang YC, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000; 160: 1612-1617.
6. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. Br Med J 2002; 325: 1073-1075.
7. Levi M, Eerenberg E, Kamphuisen PW. Periprocedural reversal and bridging of anticoagulant treatment. Neth J Med 2011; 69: 268-273.
8. Libby EN, Garcia DA. A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med 2002; 162: 1893-1896.
9. Watson HG, Baglin T, Laidlaw SL, et al. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115: 145-149.
10. Garcia D, Crowther MA, Ageno W. Practical management of coagulopathy associated with warfarin. Br Med J 2010; 340: c1813.
11. Lin Y, Callum J. Emergency reversal of warfarin anticoagulation. CMAJ 2010; 182: 2004.
12. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349: 675-683.
13. Recommendations for use of Octaplex® in Canada NAC Octaplex® Subcommittee National Advisory Committee and Blood and Blood Products; 2008; pp. 1-6.
14. NAC PCC Working Group. Recommendations for Use of Prothrombin Complex Concentrates in Canada. National Advisory Committee and Blood and Blood Products. 2011; 1-6.
15. van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006; 118: 313-320.
16. Koc U, Bostanci EB, Karaman K, et al. Basic Hemostatic Parameters in Patients with Long-Term Oral Anticoagulation Undergoing Cholecystectomy. J Laparoendosc Adv Surg Tech A 2011; 21: 417-425.
17. Srivastava A. Dose and response in haemophilia--optimization of factor replacement therapy. Br J Haematol 2004; 127: 12-25.
18. Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89: 748-756.
19. Hoots W. Emergency management in hemophilia. 2nd ed. Oxford, UK.: Wiley- Blackwell; 2010.
20. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 160S-98S.
21. Riess HB, Meier-Hellmann A, Motsch J, et al. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121: 9-16.
22. Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A metaanalysis. Thromb Haemost 2011; 106: 429-438.
23. Burbury KL, Milner A, Snooks B, et al. Short-term warfarin reversal for elective surgery--using low-dose intravenous vitamin K: safe, reliable and convenient. Br J Haematol 2011; 154: 626-634.